Hims & Hers Health, Inc. (NYSE:HIMS) will release its second quarter earnings report after the closing bell on Monday, Aug. 10.
Analysts expect the San Francisco, California-based company to report a quarterly loss of 5 cents per share, versus earnings of 17 cents per share in the year-ago period. The consensus estimate for Hims & Hers Health’s quarterly revenue is $730.12 million. It reported $544.83 million last year, according to Benzinga Pro.
On July 23, an Food and Drug Administration advisory panel voted to place the BPC-157 peptide on an allowed pharmacy compounding list.
Hims & Hers Health shares gained 6.5% to close at $31.59 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Considering buying HIMS stock? Here’s what analysts think:
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
